Advances in medical weight management have provided new options for adults living with obesity and excess weight. Two of the most widely discussed prescription medications are semaglutide and tirzepatide. Both have demonstrated meaningful weight loss in clinical studies when used alongside healthy lifestyle changes and ongoing medical supervision.
While these medications share several similarities, they also have important differences. Understanding how each works can help you have an informed discussion with your healthcare provider about which option may be appropriate for your individual needs.
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 (GLP-1), a hormone naturally produced by the body after eating.
GLP-1 helps regulate:
By enhancing these natural processes, semaglutide may help reduce food intake and support long-term weight management when combined with nutrition and physical activity.
Clinical studies have demonstrated significant weight loss in many adults using semaglutide as part of a comprehensive treatment plan.
Tirzepatide is the first medication in its class to activate both:
Because it targets two hormone pathways involved in appetite and metabolism, tirzepatide is often referred to as a dual incretin receptor agonist.
Like semaglutide, tirzepatide is administered as a once-weekly injection and is used alongside healthy lifestyle modifications.
Both medications:
Neither medication is intended to replace healthy lifestyle habits.
The primary difference is the addition of GIP receptor activation.
While semaglutide works only through GLP-1 receptors, tirzepatide activates both GLP-1 and GIP pathways.
Researchers believe this dual mechanism may contribute to additional metabolic effects, including improvements in appetite regulation, glucose metabolism and body weight for some patients.
Both medications have demonstrated meaningful weight loss in large clinical trials.
Studies evaluating semaglutide have shown substantial weight reduction compared with lifestyle modifications alone.
Clinical trials evaluating tirzepatide have also demonstrated significant weight loss, with some studies reporting greater average reductions in body weight than previously observed with GLP-1 receptor agonists alone.
Although research comparing the medications directly continues to evolve, individual response varies considerably from person to person.
Healthcare providers consider many factors—not simply average study results—when recommending treatment.
There is no single "best" medication for everyone.
The most appropriate option depends on factors such as:
Some patients may respond better to one medication than another, while others may tolerate one treatment more comfortably.
Your healthcare provider can help determine which option best aligns with your individual health needs.
Both medications commonly share similar side effects, including:
These side effects are often temporary and may improve as treatment progresses.
Patients should discuss any persistent or concerning symptoms with their healthcare provider.
Successful weight management involves much more than medication alone.
The best outcomes typically occur when prescription therapy is combined with:
A comprehensive, individualized approach can help support both weight loss and long-term weight maintenance.
Both semaglutide and tirzepatide have expanded the options available for evidence-based medical weight management.
A licensed healthcare provider can review your health history, discuss your goals and determine which treatment—if any—is appropriate for your individual circumstances.
Schedule a consultation with a licensed healthcare provider through TeleWellnessMD® to determine whether semaglutide, tirzepatide or another personalized treatment plan may be appropriate for your health goals.
Explore Wellness Support Options
This content is for educational and informational purposes only and should not be interpreted as medical advice. TeleWellnessMD® is a technology platform that connects patients with licensed healthcare providers. TeleWellnessMD® does not practice medicine, provide medical advice, or dispense medications. All therapies require evaluation and approval by a licensed healthcare provider. Results may vary. Prescription required.
Sources
Aronne LJ, Sattar N, Horn DB, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;392:649-661. doi:10.1056/NEJMoa2410819.
Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503-515.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
Lee CJ, Mao H, Thieu VT, Fernández Landó L, Thomas MK. Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1). Journal of the Endocrine Society. 2023;7(5):bvad056. doi:10.1210/jendso/bvad056
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.